Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Calhoun

Showing results (11-20 of 96) with videos related to

Pageof 10
Sort By:
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Diabetes Technology & Therapeutics|July 24, 2018
The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in RangeSarah Puhr, Peter Calhoun, John B Welsh, et al.
Diabetes Technology & Therapeutics|November 19, 2013
Evaluation of stochastic adjustment for glucose sensor bias during closed-loop insulin deliveryCraig Kollman, Peter Calhoun, John Lum, et al.
Diabetes Technology & Therapeutics|December 28, 2021
Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE StudyGeorgia Davis, Ryan Bailey, Peter Calhoun, et al.
Journal of Diabetes and Its Complications|February 21, 2021
Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic RegistryFrancesco Vendrame, Peter Calhoun, Laura E Bocchino, et al.
Diabetes Technology & Therapeutics|February 15, 2023
Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without DiabetesViral N Shah, Tim Vigers, Laura Pyle, et al.
Diabetes Technology & Therapeutics|May 23, 2022
Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND TrialsNorbert Hermanns, Dominic Ehrmann, Lutz Heinemann, et al.
Journal of Diabetes Science and Technology|January 17, 2018
Resistance to Acetaminophen Interference in a Novel Continuous Glucose Monitoring SystemPeter Calhoun, Terri Kang Johnson, Jonathan Hughes, et al.
Journal of Diabetes Science and Technology|April 26, 2026
MetaboNet: The Largest Publicly Available Consolidated Data Set for Type 1 Diabetes ManagementMiriam Kopperstad Wolff, Peter Calhoun, Eleonora Maria Aiello, et al.
Pageof 10

Showing results (11-20 of 96) with videos related to

Sort By:
Pageof 10
Diabetes Technology & Therapeutics|October 23, 2023
A Comparison of Continuous Glucose Monitoring-Measured Time-in-Range 70-180 mg/dL Versus Time-in-Tight-Range 70-140 mg/dLRoy W Beck, Dan Raghinaru, Peter Calhoun, et al.
Diabetes Technology & Therapeutics|August 3, 2022
The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized TrialDan Raghinaru, Peter Calhoun, Richard M Bergenstal, et al.
Diabetes Technology & Therapeutics|July 24, 2018
The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in RangeSarah Puhr, Peter Calhoun, John B Welsh, et al.
Diabetes Technology & Therapeutics|November 19, 2013
Evaluation of stochastic adjustment for glucose sensor bias during closed-loop insulin deliveryCraig Kollman, Peter Calhoun, John Lum, et al.
Diabetes Technology & Therapeutics|December 28, 2021
Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE StudyGeorgia Davis, Ryan Bailey, Peter Calhoun, et al.
Journal of Diabetes and Its Complications|February 21, 2021
Impact of bariatric surgery and weight loss medications in adults with type 1 diabetes in the T1D Exchange Clinic RegistryFrancesco Vendrame, Peter Calhoun, Laura E Bocchino, et al.
Diabetes Technology & Therapeutics|February 15, 2023
Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without DiabetesViral N Shah, Tim Vigers, Laura Pyle, et al.
Diabetes Technology & Therapeutics|May 23, 2022
Real-Time Continuous Glucose Monitoring Can Predict Severe Hypoglycemia in People with Type 1 Diabetes: Combined Analysis of the HypoDE and DIAMOND TrialsNorbert Hermanns, Dominic Ehrmann, Lutz Heinemann, et al.
Journal of Diabetes Science and Technology|January 17, 2018
Resistance to Acetaminophen Interference in a Novel Continuous Glucose Monitoring SystemPeter Calhoun, Terri Kang Johnson, Jonathan Hughes, et al.
Journal of Diabetes Science and Technology|April 26, 2026
MetaboNet: The Largest Publicly Available Consolidated Data Set for Type 1 Diabetes ManagementMiriam Kopperstad Wolff, Peter Calhoun, Eleonora Maria Aiello, et al.
Pageof 10